Physician profile
Shari Calicker
NPI 1962815522
$1,108.92
in general payments reported to CMS, 2019-2025
13 companies · $22.28 in 2025
The $22.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $190 · 2021: $183 · 2022: $11.99 · 2023: $160 · 2024: $256 · 2025: $22.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.42 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $202.44 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $83.14 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $59.22 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.32 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $33.37 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $25.55 | 2023 | |
| Abbott Laboratories | $22.28 | 2025 | Freestyle Libre 3 |
| Hikma Pharmaceuticals USA | $21.85 | 2023 | Kloxxado, Ryaltris, Mitigare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2023 | Jardiance |
| Lilly USA, LLC | $14.92 | 2019 | |
| Global Blood Therapeutics, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Calicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.